	US 12,285,465 B2
	Combined treatment of primary central nervous system lymphoma
Angelo Corti, Milan (IT); and Andrés José Maria Ferreri, Milan (IT)
Assigned to FONDAZIONE CENTRO SAN RAFFAELE, Milan (IT)
Appl. No. 17/297,794
Filed by FONDAZIONE CENTRO SAN RAFFAELE, Milan (IT)
PCT Filed Dec. 2, 2019, PCT No. PCT/EP2019/083322 § 371(c)(1), (2) Date May 27, 2021, PCT Pub. No. WO2020/109625, PCT Pub. Date Jun. 4, 2020.
Claims priority of provisional application 62/773,473, filed on Nov. 30, 2018.
Prior Publication US 2022/0008513 A1, Jan. 13, 2022
Int. Cl. A61K 38/19 (2006.01); A61K 31/475 (2006.01); A61K 31/573 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)

CPC A61K 38/191 (2013.01) [A61K 31/475 (2013.01); A61K 31/573 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01)]

7 Claims

1. A method for the treatment of primary central nervous system lymphoma in a subject, comprising administering a combination of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and NGR-hTNF or an analog thereof:

wherein NGR-hTNF or of an analog thereof is administered after the administration of rituximab and before the administration of CHOP drugs cyclophosphamide, doxorubicin, vincristine and prednisone and wherein the analog of NGR-hTNF is selected from the group consisting of CNGRCVSGCAGRC (SEQ ID NO: 2), NGRAHA (SEQ ID NO: 3), GNGRG (SEQ ID NO: 4), cycloCVLNGRMEC (SEQ ID NO: 5) cycloCNGRC (SEQ ID NO: 6), or CNGRC (SEQ ID NO: 7).